| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
|---|
| What is an ATC-Code? | ATC-Overview |
|
| | | IP | | | Akineton | 5 ampoule(s) | 3.11 | 12.60 | 10 % | | Injection solution: Biperideni Lactas 5 mg/ml | Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso | B / SL | FB | | G |  |
| | | IP | CI | | Akineton | 50 Tablet(s) | 4.24 | 13.85 | 10 % | | Tablets: Biperideni Hydrochloridum 2 mg | Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso | B / SL | FB | | G | |
| | | IP | CI | | Akineton retard | 30 Tablet(s) | 5.94 | 15.70 | 10 % | | compressa a rilascio prolungato: Biperideni Hydrochloridum 4 mg | Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso | B / SL | FB | | G | |
| | | IP | CI | | Akineton retard | 100 Tablet(s) | 17.94 | 35.95 | 10 % | | compressa a rilascio prolungato: Biperideni Hydrochloridum 4 mg | Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso | B / SL | FB | | G | |
| | | IP | CI | | Akineton | 20 Tablet(s) | 2.43 | 6.90 | k.A. | | Tablets: Biperideni Hydrochloridum 2 mg | Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso | B | FB | | G | |
|
| | | IP | CI | | Madopar 62.5 - T | 100 Capsule(s) | 8.48 | 18.30 | 10 % | | Capsules: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Madopar 125 | 100 Capsule(s) | 10.29 | 27.55 | 10 % | | Capsules: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Madopar 125 - T | 30 Tablet(s) | 3.64 | 13.15 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Madopar 125 - T | 100 Tablet(s) | 10.29 | 27.55 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Madopar 250 - T | 30 Tablet(s) | 8.76 | 18.55 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Madopar 250 - T | 100 Tablet(s) | 26.64 | 44.80 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Carbidopa/Levodopa Sandoz CR
25/100 - T | 30 Tablet(s) | 4.59 | 14.25 | 10 % | | Delayed release tablets: 2 Active Agents | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Carbidopa/Levodopa Sandoz CR
25/100 - T | 100 Tablet(s) | 12.94 | 30.50 | 10 % | | Delayed release tablets: 2 Active Agents | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Carbidopa/Levodopa Sandoz CR
50/200 - T | 30 Tablet(s) | 8.52 | 25.70 | 10 % | | Delayed release tablets: 2 Active Agents | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Carbidopa/Levodopa Sandoz CR
50/200 - T | 100 Tablet(s) | 26.51 | 45.25 | 10 % | | Delayed release tablets: 2 Active Agents | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 62.5 mg (50 mg +
12.5 mg) | 100 | 5.55 | 15.25 | 10 % | | Tablets: 2 Active Agents | Devatis AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 125 mg (100 mg + 25 mg) | 30 | 3.32 | 12.85 | 10 % | | Tablets: 2 Active Agents | Devatis AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 125 mg (100 mg + 25 mg) | 100 | 9.36 | 26.60 | 10 % | | Tablets: 2 Active Agents | Devatis AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 250 mg (200 mg + 50 mg) | 30 | 5.73 | 15.45 | 10 % | | Tablets: 2 Active Agents | Devatis AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 250 mg (200 mg + 50 mg) | 100 | 17.44 | 35.40 | 10 % | | Tablets: 2 Active Agents | Devatis AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Madopar DR | 30 Tablet(s) | 17.19 | 35.10 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | IP | CI | | Madopar DR | 100 Tablet(s) | 53.64 | 74.75 | 10 % | | Tablets: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | IP | CI | | Sinemet 25/100 mg | 30 | 5.21 | 14.90 | 10 % | | Tablets: 2 Active Agents | Organon GmbH | B / SL | FB | | G | |
| | | IP | CI | | Sinemet 25/100 mg | 100 | 14.95 | 32.70 | 10 % | | Tablets: 2 Active Agents | Organon GmbH | B / SL | FB | | G | |
| | | IP | CI | | Sinemet 25/250 mg | 30 | 7.16 | 17.00 | 10 % | | Tablets: 2 Active Agents | Organon GmbH | B / SL | FB | | G | |
| | | IP | CI | | Sinemet 25/250 mg | 100 | 22.33 | 40.70 | 10 % | | Tablets: 2 Active Agents | Organon GmbH | B / SL | FB | | G | |
| L | | IP | CI | | Duodopa | 7 Sachet(s) | 405.36 | 457.25 | 10 % | | Gel for intestinal application: 2 Active Agents | AbbVie AG | B / SL | FB | | G | |
| | | IP | CI | | Madopar LIQ 62.5 | 100 Tablet(s) | 8.48 | 18.30 | 10 % | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | IP | CI | | Madopar LIQ 125 - T | 30 Tablet(s) | 5.07 | 14.65 | 10 % | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | IP | CI | | Madopar LIQ 125 - T | 100 Tablet(s) | 14.30 | 31.65 | 10 % | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Active Agents | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | IP | CI | | Levodopa / Benserazid
Devatis 62.5 mg (50 mg +
12.5 mg) | 30 | 1.78 | 6.65 | k.A. | | Tablets: 2 Active Agents | Devatis AG | B | FB | | G | |
| | | IP | CI | | Levacin 100/25 | 30 | | | k.A. | | Delayed release tablets: 2 Active Agents | Acino Pharma AG | B | FB | | G | |
| | | IP | CI | | Levacin 100/25 | 100 | | | k.A. | | Delayed release tablets: 2 Active Agents | Acino Pharma AG | B | FB | | G | |
| | | IP | CI | | Levacin 200/50 | 30 | | | k.A. | | Delayed release tablets: 2 Active Agents | Acino Pharma AG | B | FB | | G | |
| | | IP | CI | | Levacin 200/50 | 100 | | | k.A. | | Delayed release tablets: 2 Active Agents | Acino Pharma AG | B | FB | | G | |
|
| | | IP | CI | | Stalevo 50/12.5/200 mg - T | 30 Tablet(s) | 20.15 | 38.15 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 50/12.5/200 mg - T | 100 Tablet(s) | 63.37 | 84.75 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 75/18.75/200 mg | 30 Tablet(s) | 21.07 | 39.15 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 75/18.75/200 mg | 100 Tablet(s) | 65.89 | 87.45 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 100/25/200 mg - T | 30 Tablet(s) | 21.99 | 40.15 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 100/25/200 mg - T | 100 Tablet(s) | 68.41 | 90.20 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 125/31.25/200 mg | 30 Tablet(s) | 22.78 | 41.00 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 125/31.25/200 mg | 100 Tablet(s) | 70.54 | 92.50 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 150/37.5/200 mg - T | 30 Tablet(s) | 23.56 | 41.80 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 150/37.5/200 mg - T | 100 Tablet(s) | 72.65 | 94.75 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 200/50/200 mg | 30 Tablet(s) | 25.25 | 43.65 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| | | IP | CI | | Stalevo 200/50/200 mg | 100 Tablet(s) | 77.15 | 99.60 | 10 % | | Coated tablets: 3 Active Agents | Orion Pharma AG | B / SL / SO | FB | | G | |
| L | | IP | CI | | Lecigon | 7 x 47 ml | 374.40 | 423.60 | 10 % | | Gel for intestinal application: 3 Active Agents | Spirig HealthCare AG | B / SL | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
50/12.5/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
50/12.5/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
75/18.75/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
75/18.75/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
100/25/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
100/25/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
125/31.25/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
125/31.25/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
150/37.5/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
150/37.5/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
200/50/200 mg | 30 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | CI | | Entacapon Plus Sandoz
200/50/200 mg | 100 Tablet(s) | | | k.A. | | Coated tablets: 3 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
|
| | | IP | CI | | PK-Merz | 2 x 500 ml | 17.68 | 35.65 | 10 % | | Infusion solution: Amantadini Sulfas 200mg / 500ml | Merz Pharma (Schweiz) AG | B / SL | FB | | G | |
| L | | IP | CI | | PK-Merz | 100 Tablet(s) | 9.49 | 26.75 | 10 % | | Coated tablets: Amantadini Sulfas 100 mg | Merz Pharma (Schweiz) AG | B / SL | FB | | G | |
| L | | IP | CI | | Symmetrel - T | 60 Capsule(s) | 14.76 | 32.45 | 10 % | | Capsules: Amantadini Hydrochloridum 100 mg | Novartis Pharma
Schweiz AG | B / SL | FB | | G | |
| | | IP | CI | | PK-Merz | 10 x 500 ml | 82.39 | 106.00 | 10 % | | Infusion solution: Amantadini Sulfas 200mg / 500ml | Merz Pharma (Schweiz) AG | B / SL | FB | | G | |
|
| L | | IP | CI | | Sifrol ER 0,375 mg | 10 Tablet(s) | 4.98 | 14.60 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Sifrol ER 0,75 mg | 10 Tablet(s) | 9.21 | 26.40 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Sifrol ER 0,75 mg | 30 Tablet(s) | 25.72 | 44.25 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Sifrol ER 1,5 mg | 30 Tablet(s) | 51.45 | 72.10 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Sifrol ER 3,0 mg | 30 Tablet(s) | 102.91 | 127.75 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Sifrol ER 4,5 mg | 30 Tablet(s) | 154.37 | 183.45 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| | | IP | CI | | Sifrol 0,125 mg - T | 30 Tablet(s) | 7.14 | 16.85 | 20 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| | | IP | CI | | Sifrol 0,25 mg - T | 30 Tablet(s) | 13.17 | 30.65 | 20 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| | | IP | CI | | Sifrol 0,25 mg - T | 100 Tablet(s) | 40.88 | 60.40 | 20 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| | | IP | CI | | Sifrol 0,5 mg | 100 Tablet(s) | 81.90 | 103.20 | 20 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| | | IP | CI | | Sifrol 1,0 mg | 100 Tablet(s) | 163.33 | 191.05 | 20 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum 1 mg | Boehringer Ingelheim
(Schweiz) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz
0.375 mg | 10 | 4.53 | 14.15 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz 0.75 mg | 10 | 8.38 | 25.55 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz 0.75 mg | 30 | 23.39 | 41.85 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz 1.5 mg | 30 | 46.78 | 67.30 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz 3 mg | 30 | 93.57 | 118.20 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Sandoz 4.5 mg | 30 | 140.36 | 169.05 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva
0.375 mg | 10 | 4.53 | 14.15 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva
0.75 mg | 10 | 8.38 | 25.55 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | ● B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva
0.75 mg | 30 | 23.39 | 41.85 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva 1.5 mg | 30 | 46.78 | 67.30 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Helvepharm AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva 3.0 mg | 30 | 93.56 | 118.15 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Helvepharm AG | ● B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol ER Zentiva 4.5 mg | 30 | 140.34 | 169.05 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Helvepharm AG | ● B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 0.375 mg | 10 | 4.53 | 14.15 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 0.75 mg | 10 | 8.38 | 25.55 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 0.75 mg | 30 | 23.39 | 41.85 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 1.5 mg | 30 | 46.78 | 67.30 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 3 mg | 30 | 93.56 | 118.15 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 3 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
| L | | IP | CI | | Pramipexol-Mepha ER 4.5 mg | 30 | 140.34 | 169.05 | 10 % | | Delayed release tablets: Pramipexoli Dihydrochloridum Monohydricum 4.5 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC
0.125 mg | 30 | 4.99 | 14.65 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC 0.25 mg | 30 | 11.26 | 28.70 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC 0.25 mg | 100 | 33.34 | 52.70 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC 0.5 mg | 100 | 44.88 | 65.20 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC 1 mg | 100 | 114.56 | 141.00 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum 1 mg | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Zentiva 0.125 mg | 30 | 4.98 | 14.65 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Zentiva 0.25 mg | 30 | 11.99 | 29.45 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Zentiva 0.25 mg | 100 | 33.34 | 52.70 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Zentiva 0.5 mg | 100 | 44.83 | 65.15 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Helvepharm AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Zentiva 1.0 mg | 100 | 114.56 | 141.00 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum 1 mg | Helvepharm AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol-Mepha 0.125 mg | 30 | 4.98 | 14.65 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol-Mepha 0.25 mg | 30 | 11.82 | 29.25 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol-Mepha 0.25 mg | 100 | 33.33 | 52.65 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol-Mepha 0.5 mg | 100 | 44.80 | 65.15 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol-Mepha 1.0 mg | 100 | 114.50 | 140.95 | 10 % | | Tablets: Pramipexoli Dihydrochloridum Monohydricum 1 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
| | | IP | CI | | Pramipexol Spirig HC 1.5 mg | 100 | | | k.A. | | Tablets: Pramipexoli Dihydrochloridum Monohydricum 1.5 mg | Spirig HealthCare AG | B | FB | | G | |
|
| | | IP | CI | | Cabaser 1 mg | 20 | 36.82 | 58.75 | k.A. | | Tablets: Cabergolinum 1 mg | Pfizer AG | B | FB | | G | |
| | | IP | CI | | Cabaser 2 mg | 20 | 47.29 | 70.75 | k.A. | | Tablets: Cabergolinum 2 mg | Pfizer AG | B | FB | | G | |
|
| L | | IP | CI | | Dacepton 5 mg/ml | 5 x 20 ml | 173.78 | 205.40 | 10 % | | Infusion solution: Apomorphini Hydrochloridum Hemihydricum 5 mg/ml | Medius AG | B / SL | FB | | G | |
| L | | IP | CI | | APO-go 50 mg/10 ml | 5 Fertigspritze(n) | 86.89 | 110.90 | 10 % | | Infusionslösung in einer Fertigspritze: Apomorphini Hydrochloridum Hemihydricum 50 mg | Spirig HealthCare AG | B / SL | FB | | G | |
| L | | IP | CI | | APO-go 100mg/20ml | 5 x 20 ml | 149.45 | 178.95 | 10 % | | Infusionslösung in einer Patrone: Apomorphini Hydrochloridum Hemihydricum 5 mg/ml | Spirig HealthCare AG | B / SL | FB | | G | |
| L | | IP | CI | | APO-go 10 mg/ml | 5 | 139.55 | 168.20 | 10 % | | Injektionslösung in einem Pen: Apomorphini Hydrochloridum Hemihydricum 10 mg | Spirig HealthCare AG | B / SL | FB | | G | |
| L | | IP | CI | | Dacepton 10 mg/ml | 5 x 3 ml | 139.55 | 168.20 | 10 % | | Injektionslösung in einer Patrone: Apomorphini Hydrochloridum Hemihydricum 10 mg/ml | Medius AG | B / SL | FB | | G | |
| | | IP | CI | | Apomorphin HCI Amino
10mg/ml | 10 | | | k.A. | | Injection solution: Apomorphini Hydrochloridum Hemihydricum 10 mg/ml | Amino AG, Fabrikation
pharmazeutischer und
chemischer Produkte | B | FB | | G | |
| | | IP | CI | | Apomorphin HCI Amino
10mg/ml | 10 | | | k.A. | | Injection solution: Apomorphini Hydrochloridum Hemihydricum 10 mg/ml | Amino AG, Fabrikation
pharmazeutischer und
chemischer Produkte | B | FB | | G | |
| | | IP | CI | | Apomorphin HCI Amino
10mg/ml | 100 | | | k.A. | | Injection solution: Apomorphini Hydrochloridum Hemihydricum 10 mg/ml | Amino AG, Fabrikation
pharmazeutischer und
chemischer Produkte | B | FB | | G | |
| | | IP | CI | | APO-go 50 mg/10 ml | 10 Fertigspritze(n) | | | k.A. | | Infusionslösung in einer Fertigspritze: Apomorphini Hydrochloridum Hemihydricum 50 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IP | CI | | APO-go 10 mg/ml | | | | k.A. | | Injektionslösung in einem Pen: Apomorphini Hydrochloridum Hemihydricum 10 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IP | CI | | APO-go 10 mg/ml | 10 | | | k.A. | | Injektionslösung in einem Pen: Apomorphini Hydrochloridum Hemihydricum 10 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IP | CI | | Dacepton 10 mg/ml | 30 x 3 ml | | | k.A. | | Injektionslösung in einer Patrone: Apomorphini Hydrochloridum Hemihydricum 10 mg/ml | Medius AG | B | FB | | G | |
| | | IP | | | Apomorphinium chloratum
Streuli 2 mg/mL | 10 ampoule(s) | | | k.A. | | Injection solution: Apomorphini Hydrochloridum 2 mg | G. Streuli & Co. AG | B | FB | | G | |
| | | IP | | | Apomorphinium chloratum
Streuli 5 mg/mL | 10 ampoule(s) | | | k.A. | | Injection solution: Apomorphini Hydrochloridum 5 mg | G. Streuli & Co. AG | B | FB | | G | |
| | | IP | | | Apomorphinium chloratum
Streuli 10 mg/mL | 10 ampoule(s) | | | k.A. | | Injection solution: Apomorphini Hydrochloridum 10 mg | G. Streuli & Co. AG | B | FB | | G | |
|
| | | IP | CI | | Comtan - T | 30 | 20.80 | 39.05 | 10 % | | Coated tablets: Entacaponum 200 mg | Orion Pharma AG | B / SL | FB | | G | |
| | | IP | CI | | Comtan - T | 100 | 66.47 | 88.70 | 10 % | | Coated tablets: Entacaponum 200 mg | Orion Pharma AG | B / SL | FB | | G | |
| | | IP | CI | | Comtan - T | 30 Tablet(s) | 29.11 | 49.80 | k.A. | | Coated tablets: Entacaponum 200 mg | Orion Pharma AG | B | FB | | G | |
| | | IP | CI | | Comtan - T | 100 Tablet(s) | 93.04 | 123.20 | k.A. | | Coated tablets: Entacaponum 200 mg | Orion Pharma AG | B | FB | | G | |
|
| | | IP | CI | | Ongentys 50 mg | 30 | 127.32 | 154.90 | 10 % | | Capsules: Opicaponum 50 mg | Bial SA | B / SL | FB | | G | |
| | | IP | CI | | Ongentys 50 mg | 90 | 381.94 | 431.80 | 10 % | | Capsules: Opicaponum 50 mg | Bial SA | B / SL | FB | | G | |
| | | IP | CI | | Ongentys 50 mg | 10 | | | k.A. | | Capsules: Opicaponum 50 mg | Bial SA | B | FB | | G | |
